TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31930414

Group type: EXPERIMENTAL
Intervention: Cortical button
Number of subjects: 42

Group type: COMPARATOR
Intervention: Interference screw
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Double-loaded 2.9-mm polyetheretherketone anchor (DL-2.9)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Double-loaded 1.9-mm all-suture anchor (DL-1.9)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Single-loaded 1.7-mm all-suture anchor (SL-1.7)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Soft tissue tenodesis
Number of subjects: 42
Study: 29605500

Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment (N=98)
Number of subjects: 174

Group type: COMPARATOR
Intervention: High SPN
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Change from low to high SPN
Number of subjects: 174

Group type: COMPARATOR
Intervention: High MPN
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Change from low to high MPN
Number of subjects: 174
Study: 26956698

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) 400 mg and Velpatasvir (VEL) 100 mg for 12 weeks
Number of subjects: 740

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study: 25694008

Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal shockwave therapy (LI-ESWT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo/sham therapy
Number of subjects: 135
Study: 23206923

Group type: EXPERIMENTAL
Intervention: Lower baseline total cholesterol levels
Number of subjects: 3957

Group type: EXPERIMENTAL
Intervention: Lower baseline triglyceride levels
Number of subjects: 3957
Study: 21672334

Group type: EXPERIMENTAL
Intervention: 70 mg alendronate once every 2 weeks plus 0.5 μg alfacalcidol daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: alfacalcidol 0.5 μg daily alone
Number of subjects: 180
Study: 19364334

Group type: EXPERIMENTAL
Intervention: Venom Immunotherapy (VIT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: EpiPen
Number of subjects: 55
Study: 16394086

Group type: EXPERIMENTAL
Intervention: 15% glucose (200 mg/m2.min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: saline (50 ml/h)
Number of subjects: 16
Study: 15333400

Group type: EXPERIMENTAL
Intervention: Ropivacaine 15 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bupivacaine 10 mg
Number of subjects: 90
Study: 11096165

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg)
Number of subjects: 632

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 632
Study: 9116923

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8380687

Group type: COMPARATOR
Intervention: 254‐S
Number of subjects: 0

Group type: COMPARATOR
Intervention: DWA2114R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cisplatinum
Number of subjects: 0
Study: 2901609

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 150
Study: 31786652

Group type: EXPERIMENTAL
Intervention: Random forest model based on pre-treatment ADC image-derived radiomics features
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Random forest model based on the top 10 most relevant features
Number of subjects: 89
Study: 29652081

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 227

Group type: COMPARATOR
Intervention: High ligation and surgical stripping (HL/S)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 227
Study: 28760799

Group type: EXPERIMENTAL
Intervention: High FIO2 group (80% oxygen; FIO2 of 0.80)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Conventional FIO2 group (30% oxygen; FIO2 of 0.30)
Number of subjects: 756
Study: 26277172

Group type: EXPERIMENTAL
Intervention: Maternal serum concentrations of NO in women with premature delivery
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Maternal serum concentrations of NO in patients with spontaneous uterine activity without PROM
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hemoglobin levels
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 73
Study: 22612371

Group type: EXPERIMENTAL
Intervention: EMD + HA/β‐TCP
Number of subjects: 34

Group type: COMPARATOR
Intervention: OFD
Number of subjects: 34

Group type: COMPARATOR
Intervention: EMD
Number of subjects: 34
Study: 21364992

Group type: EXPERIMENTAL
Intervention: Visual information and participant's prior expectations regarding basic intentions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual information and participant's prior expectations regarding superordinate intentions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual information and participant's prior expectations regarding social intentions
Number of subjects: 0
Study: 18676227

Group type: EXPERIMENTAL
Intervention: Fusidic acid (1 g)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cefepime (2 g)
Number of subjects: 30
Study: 16822633

Group type: EXPERIMENTAL
Intervention: Azithromycin formulation 1
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azithromycin formulation 2
Number of subjects: 24
Study: 12838698

Group type: EXPERIMENTAL
Intervention: Topical application of Oratest
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rinse application of Oratest
Number of subjects: 60
Study: 10393397

Group type: EXPERIMENTAL
Intervention: Bolus enalaprilat (0.004 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous enalaprilat infusion (0.004 mg/kg)
Number of subjects: 20
Study: 8913991

Group type: EXPERIMENTAL
Intervention: ABMT plus AA/Alanon (AA/ABMT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ABMT plus relapse prevention (RP/ABMT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: ABMT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AA/ABMT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AA attendance patterns
Number of subjects: 90
Study: 1676233

Group type: EXPERIMENTAL
Intervention: 500 micrograms/kg edrophonium (EDRO500)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1000 micrograms/kg edrophonium (EDRO1000)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg neostigmine (NEO40)
Number of subjects: 18
Study: 6214925

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 65
Study: 31116848

Group type: COMPARATOR
Intervention: Sham-CPAP
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conservative Medical Therapy (CMT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Active-CPAP
Number of subjects: 128
Study: 28726767

Group type: EXPERIMENTAL
Intervention: Fat taste sensitivity (FTT) assessed by 3-alternate forced choice methodology
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 69
Study: 26459006

Group type: EXPERIMENTAL
Intervention: Shinbaro pharmacopuncture
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (conventional medication and physical therapy)
Number of subjects: 60
Study: 23417014

Group type: EXPERIMENTAL
Intervention: Baseline motivation and longitudinal changes in motivation during a 26-week vocational rehabilitation program
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Cognition at baseline
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 123
Study: 21859266

Group type: EXPERIMENTAL
Intervention: Pirfenidone (Esbriet(®))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18719941

Group type: EXPERIMENTAL
Intervention: OXXEL (oxaliplatin 100 mg/m² i.v. on day 1, capecitabine 1,000 mg/m² orally twice daily from day 1 to day 11)
Number of subjects: 322

Group type: COMPARATOR
Intervention: OXAFAFU (oxaliplatin 85 mg/m² i.v. on day 1; 6S‐leucovorin 250 mg/m² i.v. and fluorouracil 850 mg/m² i.v. on day 2)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: OXXEL
Number of subjects: 322

Group type: COMPARATOR
Intervention: OXAFAFU
Number of subjects: 322
Study: 17138634

Group type: EXPERIMENTAL
Intervention: Acute exhaustive exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rest (control)
Number of subjects: 12
Study: 15488877

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg combined with Ramipril 10 mg
Number of subjects: 32
Study: 11469424

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 97

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 97
Study: 9630850

Group type: EXPERIMENTAL
Intervention: Nerve preservation (Group I)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Nerve section (Group II)
Number of subjects: 128
Study: 8163828

Group type: EXPERIMENTAL
Intervention: 10(7) cfu
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10(8) cfu
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10(9) cfu
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 30
Study: 3422243

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.001 molar solution of quinine hydrochloride (placebo rinse)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 24
Study: 31068396

Group type: EXPERIMENTAL
Intervention: Live condition (up to 3 live call reminders)
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Combined automated plus live condition (text message prompt, 2 automated call reminders, and up to 3 live reminders)
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Automated condition (text message prompt and 2 automated phone call reminders)
Number of subjects: 1767
Study: 28277487

Group type: EXPERIMENTAL
Intervention: imPACT
Number of subjects: 405

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 405
Study: 25682232

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 2103

Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg
Number of subjects: 2103

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg
Number of subjects: 2103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2103
Study: 23295684

Group type: EXPERIMENTAL
Intervention: 3D ultrasonography (3DUS) using spatiotemporal image correlation (STIC) method
Number of subjects: 328
Study: 21471304

Group type: EXPERIMENTAL
Intervention: Information about harms of waterpipe smoking
Number of subjects: 203

Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 203
Study: 19058914

Group type: EXPERIMENTAL
Intervention: Pricking pain (60ms pulse duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Burning pain (2.0s pulse duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pricking and burning pain (both conditions)
Number of subjects: 0
Study: 16525097

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg twice a day for 3 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg twice a day for 5 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg three times a day for 3 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Quinine (30 mg/kg/day divided every 8 hours for 3 days) + Doxycycline (100 mg twice a day for 7 days)
Number of subjects: 61
Study: 14571236

Group type: EXPERIMENTAL
Intervention: Palivizumab (15 mg/kg, intramuscularly, 5 monthly injections)
Number of subjects: 1287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1287
Study: 11314410

Group type: EXPERIMENTAL
Intervention: Ferric sulfate 15.5% solution (applied for 15 seconds)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Formocresol solution (five minute procedure of Buckley's formula)
Number of subjects: 70
Study: 8994331

Group type: EXPERIMENTAL
Intervention: Parkryl (Mei-Shih), 10 mg per day as an adjunct to Madopar
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Jumexal (Labatec), 10 mg per day as an adjunct to Madopar
Number of subjects: 20
Study: 1637548

Group type: EXPERIMENTAL
Intervention: 0.5-microns H2SO4 aerosol at approximately 100 micrograms/m3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5-microns carbon aerosol at approximately 250 micrograms/m3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carbon aerosol plus approximately 100 micrograms/m3 of ultrafine H2SO4 aerosol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 30
Study: 6546806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pirenzepine, 50 mg twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Benzilonium bromide, 17.5 mg twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Benzilonium bromide, 35 mg twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Benzilonium bromide, 70 mg twice daily
Number of subjects: 11
Study: 31026738

Group type: EXPERIMENTAL
Intervention: Brazil nut group (BN), consumed 1 unit/d of Brazil nuts (∼ 1261 μg/Se) for 2 months.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (CO), did not receive any intervention for 2 months.
Number of subjects: 55
Study: 29136476

Group type: EXPERIMENTAL
Intervention: Healthy Habits Program (HHP)
Number of subjects: 158
Study: 27620390

Group type: EXPERIMENTAL
Intervention: Achieved SBP of 130 to 140 mm Hg in patients aged 50 to <60 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achieved SBP of ≥140 mm Hg in patients aged 50 to <60 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achieved SBP of 130 to 140 mm Hg in patients aged ≥60 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achieved SBP of ≥150 mm Hg in patients aged ≥60 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achieved SBP of 140 to 150 mm Hg in patients aged ≥60 years
Number of subjects: 0
Study: 25496165

Group type: EXPERIMENTAL
Intervention: HLA-matched graft
Number of subjects: 654

Group type: COMPARATOR
Intervention: Random graft
Number of subjects: 654
Study: 22498739

Group type: EXPERIMENTAL
Intervention: IV zoledronic acid (ZOL)
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, thalidomide, and dexamethasone (CTD)
Number of subjects: 1960

Group type: COMPARATOR
Intervention: CTDa (attenuated oral CTD)
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Thalidomide-containing regimens
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: ZOL
Number of subjects: 1960
Study: 20420797

Group type: EXPERIMENTAL
Intervention: Chewed lanthanum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Crushed lanthanum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Meal alone
Number of subjects: 12
Study: 18539106

Group type: EXPERIMENTAL
Intervention: Denosumab every 3 months (Q3M; 6, 14, or 30 mg) or every 6 months (Q6M; 14, 60, 100, or 210 mg)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Discontinuation of denosumab
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Retreatment with denosumab (60 mg Q6M)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Open-label oral alendronate weekly
Number of subjects: 412
Study: 16182978

Group type: EXPERIMENTAL
Intervention: Specialized emergency nurses (SENs) applying Ottawa Ankle Rules (OAR)
Number of subjects: 106

Group type: COMPARATOR
Intervention: House officers (HO) applying Ottawa Ankle Rules (OAR)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Specialized emergency nurses (SENs) applying Ottawa Foot Rules (OFR)
Number of subjects: 106

Group type: COMPARATOR
Intervention: House officers (HO) applying Ottawa Foot Rules (OFR)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall interobserver agreement for OAR
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall interobserver agreement for OFR
Number of subjects: 106
Study: 12867686

Group type: EXPERIMENTAL
Intervention: Ketoprofen 2mg/kg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Pethidine 1mg/kg
Number of subjects: 86
Study: 10557173

Group type: EXPERIMENTAL
Intervention: Intra-articular irrigation injection therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Intra-articular injection of steroid (Control)
Number of subjects: 63
Study: 8687089

Group type: EXPERIMENTAL
Intervention: Cefuroxime prophylaxis (3 g intravenous dose during induction of anaesthesia)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no cefuroxime prophylaxis)
Number of subjects: 162
Study: 2104681

Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK-OP) 50 nanograms per kilogram intravenously over a ten minute period daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline solution (placebo) intravenously
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cholecystokinin-octapeptide (CCK-OP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 15
Study: 318736

Group type: EXPERIMENTAL
Intervention: DES-exposed males
Number of subjects: 696

Group type: COMPARATOR
Intervention: Control males
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: DES-exposed females
Number of subjects: 696

Group type: COMPARATOR
Intervention: Control females
Number of subjects: 696
Study: 31373036

Group type: EXPERIMENTAL
Intervention: Placebo drink (presumed energy drink information)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard water drink information
Number of subjects: 48
Study: 29958619

Group type: EXPERIMENTAL
Intervention: Written discharge instructions in Spanish
Number of subjects: 20

Group type: COMPARATOR
Intervention: Written discharge instructions in English
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Survey on patient satisfaction and preferences
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 20
Study: 27058204

Group type: EXPERIMENTAL
Intervention: Early rehabilitation and mobilization in addition to standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 23241084

Group type: EXPERIMENTAL
Intervention: High cost sharing plans (95%)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Low cost sharing plans (0, 25, 50%)
Number of subjects: 2000
Study: 24094019

Group type: EXPERIMENTAL
Intervention: Elastic ligatures aged in the oral environment for 4 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group of elastic ligatures not subjected to oral degradation
Number of subjects: 5
Study: 20714187

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab 1.25 mg
Number of subjects: 18
Study: 18450878

Group type: EXPERIMENTAL
Intervention: Observation therapy without prescription
Number of subjects: 232

Group type: COMPARATOR
Intervention: Observation therapy with prescription
Number of subjects: 232
Study: 16543909

Group type: EXPERIMENTAL
Intervention: Pharmacist/physician collaboration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNC 7 measurement tool
Number of subjects: 0
Study: 12694003

Group type: EXPERIMENTAL
Intervention: Mechanical cleaning plus thermal disinfection at 90 degrees C
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mechanical cleaning plus thermal disinfection at 90 degrees C followed by steam sterilisation at 134 degrees C
Number of subjects: 14
Study: 11574363

Group type: EXPERIMENTAL
Intervention: rapacuronium 1.2 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rapacuronium 1.0 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rocuronium 0.50 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: saline 0.05 mL/kg
Number of subjects: 80
Study: 9763797

Group type: EXPERIMENTAL
Intervention: 50% of VO2max
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 60% of VO2max
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 70% of VO2max
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80% of VO2max
Number of subjects: 30
Study: 8298866

Group type: EXPERIMENTAL
Intervention: Tilted, optimized non-saturating excitation (TONE) customized RF pulses
Number of subjects: 10

Group type: COMPARATOR
Intervention: FISP‐3D (Fast Imaging Steady Precession) pulse sequences without TONE
Number of subjects: 10
Study: 3354808

Group type: EXPERIMENTAL
Intervention: bupivacaine 30 mg plus buprenorphine 0.03 mg (group B, n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: bupivacaine 30 mg plus buprenorphine 0.045 mg (group C, n = 30)
Number of subjects: 90

Group type: COMPARATOR
Intervention: bupivacaine 30 mg (group A, n = 30)
Number of subjects: 90
Study: 8445413

Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy (ASI) with autologous tumor cell-BCG vaccine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy (ASI)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Resection alone
Number of subjects: 80
Study: 354840

Group type: EXPERIMENTAL
Intervention: Benzopyranoperidine 2 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Benzopyranoperidine 4 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Codeine sulfate 60 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Codeine sulfate 120 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31417244

Group type: EXPERIMENTAL
Intervention: Head lift exercise (HLE)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 23
Study: 27321436

Group type: EXPERIMENTAL
Intervention: Allergen exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co-exposure to allergen and diesel exhaust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allergen followed by diesel exhaust exposure (4 weeks apart)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diesel exhaust followed by allergen exposure (4 weeks apart)
Number of subjects: 0
Study: 27573034

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1212

Group type: COMPARATOR
Intervention: MED
Number of subjects: 1212
Study: 24352875

Group type: EXPERIMENTAL
Intervention: CHELT (Cold air and High Energy Laser Therapy)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ESWT (Extracorporeal Shock Waves Therapy)
Number of subjects: 60